

Myths and facts about Menopause and HRT

Matina Iliodromiti, PhD, MD, MSc, MRCOG Professor of Obstetrics and Gynaecology Research Lead Women's Health, Bart's Health Unit Lead for Women's Health, QMUL

Myth: One size does fit all Onset of menopause and symptoms vary

Average age of menopause is 51 y in the UK

Over the age of 45

- Perimenopause: Irregular periods and symptoms that can start 5-8 years before periods stop
- Menopause: No periods for 12 months
- No need for laboratory confirmation
- Bloods will not predict menopause
- Women should seek treatment if symptomatic



Premature Ovarian Insufficiency (POI)

- < 40years with no periods or less frequent periods (1%)
- Blood test can be helpful: High FSH hormone x2 will be helpful
- Exclude other medical conditions




Treatment of POI with HRT

- Regardless of symptoms treatment should be offered
- Increased risk of mortality (80% risk of heart attack and 50% of fractures- 65% osteopenia)
- Treatment with contraceptive pill or HRT
- No greater risk of breast cancer until the average age of menopause
- Benefits outweigh any risks until the average age of menopause



Myth: It is just hot flushes


Other Menopausal Symptoms- Only 1 in 2 women seek treatment






Myth: Hot flushes will go away soon Hot flushes affect 70% of women and can last for over 11 years

Prevalence of Hot flushes



Duration of Hot flushes





HRT: the most effective treatment against hot flushes and night sweats

	Number of trials	Number of hot flashes per day (mean difference 95% CI)	Number of hot flash (mean difference	
Oestrogen				
Transdermal oestradiol	6	-3·2 (-5·1 to -1·5)		
Oral oestrogen	9	-2·6 (-3·3 to -1·9)	•	
Oestrogen+progestagen	3	-2·8 (-3·8 to -1·8)	•	
Oestrogen alone	6	-2·1 (-2·9 to -1·2)	•	
Gabapentin	2	-2·05 (-2·80 to -1·30)	•	
SSRI/SNRI antidepressants	7	-1-13 (-1-70 to -0-57)	•	
Paroxetine	2	-1-66 (-2-43 to -0-89)	•	
Fluoxetine	2	-1-37 (-3-03 to 0-29)	-	
Venlafaxine	2	-0·49 (-2·40 to 1·41)	-	•
Citalopram	1	-0·20 (-1·45 to 1·05)	-	
Clonidine	4	-0-95 (-1-44 to -0-47)	•	
Soy-extract isoflavones	5	-1·15 (-2·33 to 0·03)	•	
Red-clover isoflavones	6	-0·44 (-1·47 to 0·58)	-	
		_8 _	6 -4 -2 0	2 4 6 8
		Favou	rs therapy	Favours placebo



What is Hormone Replacement Therapy (HRT)

- Oestrogen
- Progestogen either a synthetic version of the hormone progesterone, or a version called micronised progesterone (sometimes called body identical, or natural)

- Combined HRT- cyclical (peri-menopause/ within a year) or continuous
- Oestrogen only- when womb has been removed (hysterectomy)



Types of HRT



- Individualized approach
 Transdermal lower risk of blood clots



women today face a stark warning over links between HRT and breast cancer.

By Beezy Marsh Health Correspondent those taking the most common form of HRT for ten years. breast cancer.

A massive British study of a million women found the risk of cancer can be twice as high for


the past ten years. HRT taken by 1.7million women in Britain to relieve symptoms of the menopause, was already at the centre of growing concern over cancer, heart disease and strokes. The new study, published in the Lancet today, provides conclusive

HRT: does not increase breast cancer mortality

- No risk when Oestrogen only or combined with micro-ionized progesterone
- Possible small risk of Breast Cancer over the age of 50 years when combined and when over 5 years
- No greater risk of Breast cancer mortality
- Risk is regressed to background after 5 years of discontinuation




5 year HRT is safer than drinking 2 units/ day or being obese





Transdermal HRT does not increase the risk of clots This is irrespective the dose

Different types of HRT	Odds ratio (95% CI)	Odds ratio (95% CI)
Oestrogen only oral HRT		
Conjugated equine oestrogen	1.49 (1.39 to 1.60)*	
Estradiol	1.27 (1.16 to 1.39)*	-0-
Combined oral HRT		
Conjugated equine oestrogen		
Medroxyprogesterone	2.10 (1.92 to 2.31)*	
Norgestrel	1.73 (1.57 to 1.91)*	
Estradiol		
Medroxyprogesterone	1.44 (1.09 to 1.89)*	
Dydrogesterone	1.18 (0.98 to 1.42)	
Norethisterone	1.68 (1.57 to 1.80)*	-
Norgestrel/drospirenone	1.42 (1.00 to 2.03)	
Transdermal HRT		
Estradiol	0.96 (0.88 to 1.04)	*
Combined estradiol	0.86 (0.73 to 1.01)	
Otner menopausai tnerapy		
Tibolone	1.02 (0.90 to 1.15)	-
Raloxifene	1.49 (1.24 to 1.79)*	






HRT does not increase the risk of heart attack or stroke up to the age of 60 years


	CEE+MPA Trial					CEE Alone Trial						
Primary Endpoints Coronary heart disease	Active N(%*)		Diff per 10K pys*	HR	95%CI	P-trend	Active N(%*)	Placebo N(%*)	Diff per 10K pys^	HR	95%CI	P-trend
50-59	38/0 233	27/0 17)	45	1.34	(0.82 2.19)	0.81	21(0.17)	35(0.28)	-11	0.60	0.35 1.00	0.08
60-69 70-79	79(0.37) 79(0.82)	73(0.37) 59(0.63)	+19		(0.73, 1.39) (0.93, 1.84)		100(0.61) 83(0.97)	108(0.63) 79(0.90)	-3 +7	0.95	(0.72, 1.24) (0.80, 1.49)	4/4/4/20


26(0.15) 16(0.10) +5 1.51 (0	0.81, 2.82) 0.50 19(0.16)	21(0.17) -1	0.99 (0.53, 1.85)	0.77
72(0.34) 46(0.23) +11 1.45 (1	.00, 2.11) 84(0.51)	57(0.33) +18	1.55 (1.10, 2.16)	
61(0.63) 47(0.50) +13 1.22 (0	.84, 1.79) 66(0.77)	52(0.59) +17	1.29 (0.90, 1.86)	
61(0.63) 47(0.50) +13 1.22 (0	.84,	1.79) 66(0.77)	1.79) 68(0.77) 52(0.59) +17	1.79) 68(0.77) 52(0.59) +17 1.29 (0.90, 1.86)





HRT is not contraindicated in dyslipidaemia or hypertension

















LDL-C



- Hypertension is not a contraindication for HRToptimize and monitorprefer transdermal
- Obesity is not a contraindication for HRTopportunity for lifestyle modification advice- prefer transdermal

HRT delays type 2 diabetes and improves insulin resistance Oral may be better





Diabetes incidence by treatment arm (Oestrogen Plus Progestin [O+P] versus Placebo). Hazard ratio (95% CI), 0.79 (0.67–0.93). Blue line: Oestrogen Plus Progestin; red line: Placebo



Myth: Natural alternatives or bio-identical are safer

- Less research on natural alternatives/ bio-identical
- Interaction with other medications eg anticoagulants which is less known
- Not appropriate absorption
- Individualized approach with healthier lifestyle, weight loss, exercising (strength) and less alcohol and processed food diet



Myth: Menopause means less sex

- Low oestrogen can be associated with low libido
- But less sleep/ relationship challenges/ vaginal atrophy due to menopausal symptoms exaggerate this
- HRT can contribute to improving low libido
- Testosterone can be considered



Myth: Pregnancy cannot happen while on HRT

- Small chance of pregnancy while on HRT
- Menopause and no chance of pregnancy after > 1 year of no periods without the impact of hormones/ treatment
- Contraception till 55 if on HRT (and not clear when menopause happened)



Key Facts

- Always treatment if periods stop before 40 years
- Menopausal symptoms onset can vary
- Hot flashes are the commonest symptoms can last ~7-8 years for over 50%
- Other menopausal symptoms are common too
- HRT especially oestrogen only or combined with micro-ionised progesterone does not increase the risk of breast cancer mortality
- Transdermal HRT does not increase the risk of clots
- HRT does not increase risk of stroke or heart attack up to the age of 60 years
- HRT is not contraindicated in hypertension or dyslipidaemia
- T2DM is not a contraindication for HRT
- Seek advise if symptoms- discuss with your manager too
- In most cases, HRT benefits outweigh risks when for symptom relief



THANK YOU

Ask for advice if symptoms
In most cases, HRT benefits outweigh risks when for symptom relief



s.iliodromiti@qmul.ac.uk